Athenex, Inc.(ATNX)

Description: Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

---

Keywords: Cancer Organic Compounds Oncology Radiation Chemotherapy Organic Chemistry Antineoplastic Drugs Dermatitis Nausea Therapies For Cancer Docetaxel Paclitaxel Pruritus Scars Cancer Diseases Treatment Of Various Types Of Cancers Oraxol Taxanes

---

Home Page: www.athenex.com

ATNX Technical Analysis

Conventus Building
Buffalo, NY 14203
United States
Phone: 716 427 2950

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)